Arrayit Corporation (ARYC)

[raspaman]

On March 25, 2020, Predictive Technology Group, Inc. issued a press release announcing the Launch of Assurance AB™, a rapid serology antibody test to detect the COVID-19 virus.

8K filing

website and PR

"Because of the rapid spread of the COVID-19 virus, several states including California and New York have recently expressed immediate need for rapid antibody testing. While there are benefits to viral testing, serology antibody testing allows patients to know if they have been exposed to the virus and if they have developed antibodies typically associated with immunity.

Assurance AB COVID-19 IgM/IgG Rapid Antibody Test is being manufactured in cooperation with Jiangsu Dablood Pharmaceutical CO, Ltd. Dablood Pharmaceutical has successfully distributed 38 million tests to date throughout Asia and Europe. To the best of Predictive’s knowledge, Dablood Pharmaceutical is one of very few companies approved by the Chinese government to co-develop and manufacture rapid antibody tests. Dablood Pharmaceutical is one of the largest diagnostic kit manufacturers in China and is currently producing up to 1.5 million units of the rapid antibody test per day in China. Predictive evaluated other potential developers and suppliers and believes Dablood Pharmaceutical provides not only existing inventory, its high-volume production capacity enables them to rapidly increase production to provide high-quality tests to meet rapidly expanding global demand. Dablood Pharmaceutical has been recognized by the Chinese government for its effort of developing and producing testing products to help the detect the COVID-19 and has received approval for distribution of its test across the domestic Chinese market and the European Union with a CE mark.

Predictive is also pursuing procurement authorization through the Biomedical Advance Research and Development Authority (BARDA) under the Office of the Assistant Secretary for Preparedness and Response (ASPR) in Health and Human Services (HHS). The Company cautions that if the federal government decides to restrict adequate reimbursement or the foreign import of products manufactured in Asia, the Company will not be able to provide access to these tests in the U.S.

Dablood Pharmaceutical is one of the largest diagnostic kit
manufacturers in China and is currently producing up to 1.5 million units of the rapid antibody test
per day in China.
Predictive evaluated other potential developers and suppliers and believes Dablood Pharmaceutical
provides not only existing inventory, its high-volume production capacity enables them to rapidly
increase production to provide high-quality tests to meet rapidly expanding global demand.
Dablood Pharmaceutical has been recognized by the Chinese government for its effort of developing
and producing testing products to help the detect the COVID-19 and has received approval for
distribution of its test across the domestic Chinese market and the European Union with a CE mark."

this is NOT YET LISTED ON CDC EUA website. possibility there are others?

This is what we should expect to see from ARYC